RPRD1B is highly expressed in human ovarian cancer cell lines and promotes tumor cell proliferation

doi:10.16352/j.issn.1001-6325.2025.08.1066

Abstract

Abstract: Objective To explore the role of regulation of nuclear pre-mRNA-domain-containing 1B(RPRD1B)in human ovarian cancer. Methods The expression level of RPRD1B in ovarian cancer was detected by RT-qPCR and Western blot experiments. Based on the CRISPR/Cas9 system and lentiviral system, the A2780 and SKOV3 cell lines with RPRD1B gene knockout and over-expression were respectively constructed, and their functions in ovarian cancer were verified by wound-healing assay, Transwell assay and mouse subcutaneous tumor formation model. Results RPRD1B was highly expressed in ovarian cancer cell lines (P＜0.001). Knockout of RPRD1B inhibited the colony formation and proliferation ability of ovarian cancer cells (P＜0.001), as well as the cell migration (P＜0.05) and invasion ability (P＜0.001). Meanwhile, knockout of RPRD1B inhibited the tumorigenesis ability of SKOV3 ovarian cancer cell lines in vivo (P＜0.001). Conclusions RPRD1B is highly expressed in human ovarian cancer cell lines and promotes the growth of subcutaneous tumors in mice.

Key words: regulation of nuclear pre-mRNA-domain-containing 1B (RPRD1B), ovarian cancer, proliferation

CLC Number:

TIAN Ye, HE Quan, WANG Xiaojuan. RPRD1B is highly expressed in human ovarian cancer cell lines and promotes tumor cell proliferation[J]. Basic & Clinical Medicine, 2025, 45(8): 1066-1072.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin, 2021, 71, 209-249.
[2] Jayson GC, Kohn EC, Kitchener, et al. Ovarian cancer[J]. Lancet, 2014, 384, 1376-1388.
[3] Hinchcliff E, Westin SN, Herzog TJ. State of the science: contemporary front-line treatment of advanced ovarian cancer[J]. Gynecol Oncol, 2022, 166, 18-24.
[4] Bartoletti M, Musacchio L, Giannone G, et al. Emerging molecular alterations leading to histology-specifictargeted therapies in ovarian cancer beyond PARP inhibitors[J]. Cancer Treat Rev, 2021, 101:102298. doi: 10.1016/j.ctrv.2021.102298.
[5] Gogineni V, Morand S, Staats H, et al. Current ovarian cancer maintenance strategies and promising new developments[J]. Cancer, 2021, 12:38-53.
[6] González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2019, 381:2391-2402.
[7] Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer[J]. N Engl J Med, 2019, 381:2416-2428.
[8] Li M, Ma D, Chang Z. Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers[J]. Oncogene, 2021, 40:705-716.
[9] Li W, Zheng G, Xia J, et al. Cell cycle related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in nonsmall-cell lung cancer[J]. Cancer Sci, 2018, 109:1012-1023.
[10] Jiang J, Yang X, He X, et al. MicroRNA449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/beta-catenin signaling[J]. Chem Biol Interact, 2019, 302:74-82
[11] Sun M, Si G, Sun HS, et al. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway[J]. Biochem Biophys Res Commun, 2018, 496:1183-1190.
[12] Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes[J]. Cancer Cell, 2012, 21: 92-104.
[13] Zhai W, Ye X, Wang Y, et al. CREPT/RPRD1B promotes tumorigenesis through STAT3-driven gene transcription in a p300-dependent manner[J]. Br J Cancer, 2021, 124: 1437-1448.
[14] Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT)[J]. Int J Mol Sci, 2023, 24:11386. doi: 10.3390/ijms241411386.

[1]	ZOU Qingbo, ZHANG Guochen, PAN Changjing. Gypenoside inhibits the proliferation, migration and invasion of prostate cancer cell line PC-3 [J]. Basic & Clinical Medicine, 2025, 45(8): 1059-1065.
[2]	YIN Lijun, BO Yang, Anggelema, SONG Linlin. LncRNA HIF1A-AS1 promotes the proliferation of gastric cancer cell lines through interfering with HIF1A [J]. Basic & Clinical Medicine, 2025, 45(5): 627-636.
[3]	WEI Jianxin, FANG Yanle, LU Yubo, GAO Yuguang, LANG Xing, LI Jingtao, MA Xinsheng. Artesunate inhibits proliferation and promotes apoptosis and autophagy of nephroblastoma cell line SK-NEP-1 [J]. Basic & Clinical Medicine, 2025, 45(4): 493-498.
[4]	ZHOU Jing, QU Miao. Upregulation of miR-152 inhibits proliferation and migration of human vascular smooth muscle cells induced by ox-LDL [J]. Basic & Clinical Medicine, 2025, 45(4): 486-492.
[5]	ZHANG Yao, ZHANG Xuan, JIA Anna, ZHAN Shijia, GUO Jinxin, CHANG Yan, GUO Yongli. Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro [J]. Basic & Clinical Medicine, 2025, 45(2): 168-175.
[6]	SHEN Hongmei, YU Yan, FENG Xuqiang, WANG Keqiang. Usnea acid inhibits the proliferation of human ovarian cancer cell line [J]. Basic & Clinical Medicine, 2025, 45(1): 31-37.
[7]	XIAO Yanhong, JIANG Mingdong, LIN Yeyuan, RAN Can, LIANG Bo. Scutellarin inhibits proliferation and migration of human prostate cancer cell line PC-3 [J]. Basic & Clinical Medicine, 2024, 44(9): 1229-1235.
[8]	YAO Anjun, CHEN Lingzi, JIN Huixian. Docosahexaenoic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2024, 44(8): 1107-1112.
[9]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[10]	CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue. Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926 [J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
[11]	ZHANG Pengju, LI Jie, ZHANG Mengdi, SUN Shaoke, XU Yinzhe. KAT8 promotes the proliferation of colorectal cancer cell lines by enhancing METTL3 expression [J]. Basic & Clinical Medicine, 2024, 44(7): 931-939.
[12]	GAO Yinjie, TONG Anli. Mechanisms of cell death and proliferation of aldosterone-producing adenoma [J]. Basic & Clinical Medicine, 2024, 44(6): 758-762.
[13]	WANG Tingting, XIAO Ning, LIN Dianxin, DONG Haitao. Allicin inhibits the proliferation of oral cancer cells line CAL27 [J]. Basic & Clinical Medicine, 2024, 44(5): 673-676.
[14]	JIA Anna, GUO Jinxin, ZHANG Xuan, ZHAN Shijia, YU Yongbo, GUO Yongli, CHANG Yan. Regulation of TMEFF1 on proliferation of neuroblastoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(5): 637-644.
[15]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.